Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu 210009, China.
Chin Med J (Engl). 2018 May 20;131(10):1220-1224. doi: 10.4103/0366-6999.228765.
Acute respiratory distress syndrome (ARDS) is a devastating clinical syndrome whose diagnosis and therapy are still in question. The aim of this review was to discuss the current challenge for the diagnosis and treatment of ARDS.
Data sources were the published articles in English through December 2017 in PubMed using the following key words: "acute respiratory distress syndrome," "definition", "diagnosis," "therapy," "lung protective strategy," "right ventricular dysfunction," and "molecular mechanism."
The selection of studies focused on both preclinical studies and clinical studies of therapy of ARDS.
The incidence of ARDS is still high, and ARDS causes high intensive care units admissions and high mortality. The Berlin Definition proposed in 2012 is still controversial owing to lack of sensitivity and specificity. ARDS is still under recognition and it is associated with high mortality. Lung protective strategies with low tidal volume (VT) and lung recruitment should consider the physiology of ARDS because ARDS presents lung inhomogeneity; the same low VT might increase local stress and strain in some patients with low compliance, and lung recruitment could injure lungs in ARDS patients with low recruitability and hemodynamic instability. Acute cor pulmonale is common in severe ARDS. ARDS itself and some treatments could worsen acute cor pulmonale. Molecular understanding of the pathogenic contributors to ARDS has improved, but the molecular-associated treatments are still under development.
ARDS is a devastating clinical syndrome whose incidence and mortality has remained high over the past 50 years. Its definition and treatments are still confronted with challenges, and early recognition and intervention are crucial for improving the outcomes of ARDS. More clinical studies are needed to improve early diagnosis and appropriate therapy.
急性呼吸窘迫综合征(ARDS)是一种破坏性的临床综合征,其诊断和治疗仍存在疑问。本综述的目的是讨论 ARDS 的诊断和治疗的当前挑战。
通过使用以下关键词在 PubMed 中搜索 2017 年 12 月之前发表的英文文章作为资料来源:“acute respiratory distress syndrome”,“definition”,“diagnosis”,“therapy”,“lung protective strategy”,“right ventricular dysfunction”和“molecular mechanism”。
研究选择重点是 ARDS 的临床治疗的临床前研究和临床研究。
ARDS 的发病率仍然很高,ARDS 导致重症监护病房的入住率和死亡率居高不下。2012 年提出的柏林定义由于缺乏敏感性和特异性而仍然存在争议。ARDS 的认识仍然不足,与高死亡率相关。ARDS 呈现肺不均匀性,因此采用低潮气量(VT)和肺复张的肺保护策略需要考虑 ARDS 的生理学;对于顺应性低的一些患者,相同的低 VT 可能会增加局部压力和应变,肺复张可能会损伤 ARDS 患者中顺应性低和血流动力学不稳定的肺部。急性肺心病在严重 ARDS 中很常见。ARDS 本身和某些治疗方法可使急性肺心病恶化。对 ARDS 发病机制的分子认识有所提高,但分子相关治疗仍在开发中。
ARDS 是一种破坏性的临床综合征,其发病率和死亡率在过去 50 年中一直居高不下。其定义和治疗仍面临挑战,早期识别和干预对于改善 ARDS 的预后至关重要。需要更多的临床研究来改善早期诊断和适当的治疗。